HK1048593A1 - 用於通過體內基因輸送治療心血管疾病的技術和組合物 - Google Patents
用於通過體內基因輸送治療心血管疾病的技術和組合物Info
- Publication number
- HK1048593A1 HK1048593A1 HK03100751.6A HK03100751A HK1048593A1 HK 1048593 A1 HK1048593 A1 HK 1048593A1 HK 03100751 A HK03100751 A HK 03100751A HK 1048593 A1 HK1048593 A1 HK 1048593A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vivo
- compositions
- techniques
- cardiovascular disease
- gene delivery
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 238000001476 gene delivery Methods 0.000 title 1
- 238000001727 in vivo Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43515699A | 1999-11-05 | 1999-11-05 | |
US60908000A | 2000-06-30 | 2000-06-30 | |
PCT/US2000/030345 WO2001034208A1 (en) | 1999-11-05 | 2000-11-03 | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1048593A1 true HK1048593A1 (zh) | 2003-04-11 |
Family
ID=27030448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03100751.6A HK1048593A1 (zh) | 1999-11-05 | 2003-01-29 | 用於通過體內基因輸送治療心血管疾病的技術和組合物 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1225921A1 (ja) |
JP (1) | JP2003513942A (ja) |
KR (1) | KR20020049031A (ja) |
CN (1) | CN1433325A (ja) |
AU (1) | AU784392B2 (ja) |
CA (1) | CA2389524A1 (ja) |
EA (1) | EA008538B1 (ja) |
HK (1) | HK1048593A1 (ja) |
NZ (1) | NZ546670A (ja) |
WO (1) | WO2001034208A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2389524A1 (en) * | 1999-11-05 | 2001-05-17 | The Regents Of The University Of California | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
US20030093147A1 (en) * | 2001-11-13 | 2003-05-15 | Ogle Matthew F. | Medical devices that stimulate growth factor production |
KR100562824B1 (ko) | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
PL195457B1 (pl) * | 2002-08-05 | 2007-09-28 | Zaklady Farm Polpharma Sa | Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie |
EP2044199B1 (en) * | 2006-07-25 | 2012-11-14 | Celladon Corporation | Extended antegrade epicardial coronary infusion of adeno-associated viral vectors comprising serca2a for gene therapy |
SI2197900T1 (sl) * | 2007-08-24 | 2012-11-30 | Julius Maximilians Uni Wurzburg | Mutantni dvojno ciklizirani receptorski peptidi ki inhibirajo protitelesa beta adrenoceptorja |
ES2556711T3 (es) | 2008-04-09 | 2016-01-19 | Viromed Co., Ltd. | Formulaciones liofilizadas de ADN para el aumento de la expresión del ADN plasmídico |
WO2010078624A1 (en) * | 2009-01-07 | 2010-07-15 | Vegenics Limited | Materials and methods for the treatment of hypertension |
KR101006106B1 (ko) * | 2009-06-04 | 2011-01-07 | 김현태 | 전·자기장 차단 전열선 |
US10155099B2 (en) | 2009-09-21 | 2018-12-18 | Cook Regentec Llc | Method for infusing stem cells |
IN2014DN06789A (ja) * | 2012-02-14 | 2015-05-22 | Univ California | |
JP6499578B2 (ja) | 2012-06-05 | 2019-04-10 | マフィン・インコーポレイテッドMuffin Incorporated | 細胞療法に有用なカテーテルシステム及び方法 |
BR112016008267A2 (pt) | 2013-10-22 | 2017-10-03 | Viromed Co Ltd | Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito |
US20210393805A1 (en) * | 2018-05-16 | 2021-12-23 | University Of Massachusetts | Perfusion-based delivery of recombinant aav vectors for expression of secreted proteins |
EP3823677A4 (en) | 2018-07-19 | 2022-06-01 | Helixmith Co., Ltd. | FREEZE-DRIED PHARMACEUTICAL COMPOSITIONS INTENDED FOR NAKED-DNA GENE THERAPY |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5792453A (en) * | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
US6100242A (en) * | 1995-02-28 | 2000-08-08 | The Regents Of The University Of California | Gene therapies for enhancing cardiac function |
NZ336838A (en) * | 1997-01-29 | 2002-04-26 | Cornell Res Foundation Inc | A method of enhancing the level of perfusion of blood to a target tissue by administering an adenoviral vector encoded with an angiogenic peptide within 0.5-15 cm3 of the tissue |
CN1267331A (zh) * | 1997-05-06 | 2000-09-20 | 加利福尼亚大学董事会 | 通过在体内运送血管生成转基因来治疗心力衰竭和心室重建的技术和组合物 |
CN101186928A (zh) * | 1998-02-11 | 2008-05-28 | 加利福尼亚大学董事会 | 核酸和血管活性剂相组合用于加强的基因投递 |
WO2000038518A1 (en) * | 1998-12-28 | 2000-07-06 | Arch Development Corporation | Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
CA2389524A1 (en) * | 1999-11-05 | 2001-05-17 | The Regents Of The University Of California | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
-
2000
- 2000-11-03 CA CA002389524A patent/CA2389524A1/en not_active Abandoned
- 2000-11-03 NZ NZ546670A patent/NZ546670A/en not_active IP Right Cessation
- 2000-11-03 KR KR1020027005855A patent/KR20020049031A/ko not_active Application Discontinuation
- 2000-11-03 JP JP2001536204A patent/JP2003513942A/ja active Pending
- 2000-11-03 CN CN00816481A patent/CN1433325A/zh active Pending
- 2000-11-03 WO PCT/US2000/030345 patent/WO2001034208A1/en active Application Filing
- 2000-11-03 AU AU14604/01A patent/AU784392B2/en not_active Ceased
- 2000-11-03 EP EP00976894A patent/EP1225921A1/en not_active Withdrawn
- 2000-11-03 EA EA200200533A patent/EA008538B1/ru not_active IP Right Cessation
-
2003
- 2003-01-29 HK HK03100751.6A patent/HK1048593A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001034208A1 (en) | 2001-05-17 |
EP1225921A1 (en) | 2002-07-31 |
AU1460401A (en) | 2001-06-06 |
EA008538B1 (ru) | 2007-06-29 |
CA2389524A1 (en) | 2001-05-17 |
CN1433325A (zh) | 2003-07-30 |
AU784392B2 (en) | 2006-03-23 |
NZ546670A (en) | 2009-02-28 |
EA200200533A1 (ru) | 2002-12-26 |
JP2003513942A (ja) | 2003-04-15 |
KR20020049031A (ko) | 2002-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002305346A1 (en) | Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery | |
AU3692001A (en) | Compositions and methods for enhancing drug delivery across biological membranesand tissues | |
HK1048593A1 (zh) | 用於通過體內基因輸送治療心血管疾病的技術和組合物 | |
IL144508A0 (en) | Compositions and methods for use in targeting vascular destruction | |
HK1039571A1 (en) | Compositions and methods for mucosal delivery | |
MXPA03007590A (es) | Composiciones y metodos para mejorar suministro de droga a traves de y dentro de tejidos oculares. | |
PL338846A1 (en) | Starch compositions suitable for treatment in molten state | |
HK1080724A1 (en) | Stabilized pharmaceutical composition in lyophilized form | |
EP1165586A4 (en) | TCL-1B GENES AND PROTEINS AND RELATED METHODS AND METHODS | |
HUP0203590A3 (en) | Remedies for diseases in association with decrease in bone mass | |
HUP0200275A3 (en) | Seed treatment composition and preparation thereof | |
EP1180006A4 (en) | COMPOSITIONS AND METHODS FOR PREPARING SUCH COMPOSITIONS FROM LEPIDIA | |
EP1470240A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES USING 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419 , 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2 | |
MXPA02003232A (es) | Composiciones y metodos para alternar la expresion de genes. | |
EP1583966A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASES USING GENES 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33 | |
EP1233671A4 (en) | COMPOSITIONS AND METHODS OF DISPOSING MEDICAMENTS USING AMPHIPHILIC BINDING MOLECULARS | |
EP1311192A4 (en) | -G- (IN VIVO) IMAGING | |
IL148946A0 (en) | Altering gene expression with ssdna produced in vivo | |
AU2002306461A1 (en) | In vivo delivery methods and compositions | |
ZA200203435B (en) | Method and compositions for treating pulmonary diseases. | |
IL149451A0 (en) | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery | |
ZA200203303B (en) | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery. | |
AU2002226986A1 (en) | In vivo delivery methods and compositions | |
HU0103686D0 (en) | Pharmaceutical composition for preventing or treating diseases associated with an excess in il-12 production | |
GB2349646B (en) | Two-part cleansing composition |